-
Delta mutant strains have appeared in at least 98 countries and regions
Time of Update: 2021-07-28
This mutant strain is more dangerous and continues to mutate and evolve.
-
The National Medical Science Foundation of China announced the list of experts for evaluation of four projects including Jie Qing
Time of Update: 2021-07-28
National Natural Science Fund Committee willCommittee member Department of Medical Sciences June 28, 2021
-
Patients with mild COVID-19 will have symptoms of "long-term COVID-19"
Time of Update: 2021-07-28
International war "epidemic" operation Science and Technology Daily, Beijing, June 24 (Reporter Zhang Mengran) A research analysis of patients with new coronary pneumonia published by the British "Nature Medicine" on the 24th found for the first time that more than half of young and middle-aged (16-30 years old) patients with mild illness who were isolated at home Six months after the initial infection, symptoms of long-lasting dyspnea, loss of taste and smell, fatigue or inattention, and memory loss appeared .
-
Nearly 20 original research drugs have encountered patent challenges!
Time of Update: 2021-07-28
Chongqing Yaoyou Pharmaceutical challenged the patent of this pharmaceutical preparation, and the State Intellectual Property Office made a complete invalidation decision on ZL200680007187.
Therefore, after the patent for the original compound expired, domestic generic drugs with approved document numbers flocked to the market .
-
New malaria vaccine demonstrates high levels of protection in initial trials
Time of Update: 2021-07-28
8%; In the case of being injected with malaria sporozoites combined with chloroquine, this high-dose vaccine will infect Plasmodium xenans after 3 months 100% of the protective effects were achieved on the 6 volunteers .
-
Fosun Pharma/BioNTech establishes a joint venture company in China
Time of Update: 2021-07-28
Regarding the subsequent commercialization of the vaccine, it was agreed that the joint venture company would hire an affiliate of Fosun Pharmaceutical Industry as the CSO to provide marketing and sales services for the mRNA COVID-19 vaccine in China (excluding Hong Kong, Macao and Taiwan), and pay the CSO accordingly.
-
There is no specific anti-hepatitis E virus, the key lies in prevention
Time of Update: 2021-07-28
Third Affiliated Hospital of Sun Yat-sen, vice liver disease hospital president high Zhiliang, 18, at present there is no anti-hepatitis E virus-specific drugs, the key is prevention .
Elderly people, women of childbearing age, patients with basic liver diseases and other high-risk groups are vaccinated against hepatitis E vaccine .
-
Hengrui PD-1 new indication for nasopharyngeal carcinoma will be approved soon
Time of Update: 2021-07-28
April 20, NMPA official website shows, Ka Ruili natalizumab single pharmaceutical in progress and previously treated with second-line chemotherapy after more than a disease or intolerable advanced nasopharyngeal carcinoma patients with indications for listing application (admissibility: CXSS2000045) The approval status is changed to "Pending Approval ".
-
Guocai’s "Contract Renewal Season": Is there a sharp increase in drug prices?
Time of Update: 2021-07-28
The company selected for the centralized procurement of cephalexin capsules in the second batch of national organizations is Huabei Pharmaceutical Hebei Huamin Pharmaceutical, the specification is 0.
-
Nuocheng Jianhua's new multi-target RTK inhibitor ICP-033 new drug research application was accepted by the State Food and Drug Administration
Time of Update: 2021-07-28
Biomedical high-tech company Nuocheng Jianhua announced that the company's new multi-target receptor tyrosine kinase (RTK) inhibitor ICP-033 New Drug Research (IND) application has been accepted by the National Medical Products Administration (NMPA) .
-
Hengrui PD-1 nasopharyngeal carcinoma indication is officially approved
Time of Update: 2021-07-28
April 29, NMPA official website shows, Ka Ruili natalizumab new indications approved on the market, use for previously treated with second-line chemotherapy, disease progression and after more or intolerable advanced nasopharyngeal carcinoma patients .
-
How do Qilu and Yilian Biopharmaceuticals add next-generation ADC drugs?
Time of Update: 2021-07-28
03 Conversion of IgG4 to IgG1 The first-generation ADC drug Mylotarg uses IgG4 as an antibody, but IgG4 molecules cannot cause Fc-mediated ADCC, CDC and ADCP effects.
With this technology, ADC drugs with a DAR of 10-12 can be designed, laying the foundation for the use of lower-toxic payloads .
-
The drug review report is out!
Time of Update: 2021-07-28
Priority review approved doubled The report also shows that in 2020, the Center for Drug Evaluation will complete 11,582 registration applications for Chinese medicines, chemical drugs, and biological products (including 4 device combination products, counted by acceptance numbers), an increase of 32.
-
CDE: Publicly solicit opinions on the guiding principles of 17 varieties
Time of Update: 2021-07-28
Transfer from: CDE Editor: Dandelion-Green Tea On April 12-13, CDE issued 6 notices to solicit opinions on guiding principles . The time limit for soliciting opinions is 1 month from the date of p
-
WHO: Delta mutant strain is the most easily transmitted variant of new coronavirus
Time of Update: 2021-07-28
WHO Director-General Tan Desai said that the Delta mutant strain is the most easily transmitted new crown virus mutant found so far.
Tan Desai emphasized that there will be new mutant strains in the future, and the virus will evolve, but the emergence of new mutant strains can be prevented by curbing the spread of the virus .
-
Reproductive health research is expected to bring new solutions to patients with preeclampsia
Time of Update: 2021-07-28
Academy president struggles Academy of Sciences According to reports, in 2017 China Ke Xueyuan stem cells and regeneration of the Academy of Medical Innovation Ferring Pharmaceutical jointly established FIRM, aims to integrate China's leading reproductive biology research strength and characteristics of the platform, is committed to applying the conversion reproductive biology basic research and to promote scientific research , To provide solutions for the prevention, diagnosis, treatment and rehabilitation of related diseases in the field of reproductive health.
-
International scholars: The leak theory of the new crown virus laboratory is a demonizing science
Time of Update: 2021-07-28
International scholars: the "laboratory leak theory" of the new crown virus is a demonized science. Don't let truth become a political victim International scholars: The "laborator
-
my country's new crown vaccine vaccination rate exceeds 1.1 billion doses and the vaccination rate exceeds 40%
Time of Update: 2021-07-28
By June 14, the number of inoculation doses exceeded 900 million, from 800 million to 900 million, and it took 6 days .
By June 19, the number of inoculation doses exceeded 1 billion, and it took 5 days .
-
Hengrui Class 1 new drug is close to NDA, what signals have it released
Time of Update: 2021-07-28
Not long ago, the CDK4/6 inhibitor SHR6390 developed by Jiangsu Hengrui has been submitted to the domestic NDA for breast cancer; and 1 month ago, this product was also included in the breakthrough treatment program of CDE, and the indication was combined with fluorine.
-
Centralized procurement of biopharmaceuticals is imperative, two major difficulties VS five major countermeasures
Time of Update: 2021-07-28
difficulty Clinical substitutability: the main obstacle to centralized procurement The essence of centralized procurement of drugs is to put clinically replaceable drugs together for bidding, and the lower price wins the market, thereby prompting manufacturers to quote as low prices as possible in order to realize the value pursuit of buyers .
